Menquadfi

Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid, the active ingredient in Menquadfi, is a conjugate vaccine presented as a vaccine for intramuscular use. It prevents invasive disease caused by Neisseria meningitidis serogroup C in individuals at risk.

GNH USA supplies Menquadfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menquadfi is a conjugate vaccine that targets meningococcal serogroup C disease.

Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup C: provides immunity to reduce the risk of meningitis, septicemia and related severe infections. Outbreak control in at‑risk populations: helps limit the spread of serogroup C during community or institutional outbreaks. Travel protection for persons visiting endemic areas: lowers the chance of acquiring serogroup C infection while abroad.

Common Side Effects: - Injection site pain, redness or swelling. - Mild fever or chills. - Headache. - Fatigue or malaise. - Muscle aches. - Nausea.

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction. - Guillain‑Barré syndrome. - High‑grade fever. - Seizures. - Hypotension. - Severe local inflammation or abscess formation.

Menquadfi should be administered after careful assessment of the individual's health status.

Pregnancy: consult a healthcare professional; safety data are limited. Breastfeeding: weigh potential benefits against unknown risks. Allergy: avoid if there is a known hypersensitivity to any vaccine component. Immunocompromised patients: may exhibit reduced antibody response; monitor effectiveness. Fever monitoring: treat high fever promptly and report persistent symptoms. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menquadfi may interact with other immunizations or immune‑modulating agents.

Major Interactions (Avoid): - Live vaccines: do not co‑administer within 4 weeks, as interference may reduce efficacy. - Immunoglobulin therapy: avoid within 3 months of vaccination, which can neutralize the antigen.

Moderate Interactions (Monitor Closely): - Antipyretics: may be used for post‑vaccination fever but could blunt the immune response if taken prophylactically. - Immunosuppressive drugs: may diminish antibody production; consider serologic testing. - Blood products: transfusion shortly after vaccination may affect immune priming.